Fibroblast Growth Factor 23, but not Parathyroid Hormone, Is Associated With Urinary Phosphate Regulation in Patients on Peritoneal Dialysis

Shunsuke Yamada, Kazuhiko Tsuruya, Masanori Tokumoto, Hisako Yoshida, Shoko Hasegawa, Shigeru Tanaka, Masahiro Eriguchi, Toshiaki Nakano, Kosuke Masutani, Hiroaki Ooboshi, Takanari Kitazono

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fibroblast growth factor (FGF) 23 plays an important role in regulation of renal phosphate excretion in patients with chronic kidney disease. However, it remains undetermined whether FGF23 is closely linked to renal phosphate handling in patients with low glomerular filtration rate (GFR). The present cross-sectional study included 52 outpatients undergoing peritoneal dialysis with urine volume≥100mL/day. The primary outcome was level of urinary phosphate excretion, and the secondary outcomes were tubular maximal reabsorption of phosphate normalized to GFR (TmP/GFR), an index of the renal threshold for phosphate excretion, and level of peritoneal phosphate excretion. Variates of interest were serum FGF23 and parathyroid hormone (PTH) levels. The median and interquartile range of serum FGF23 level, TmP/GFR, and total urinary and peritoneal phosphate excretion were 5610 (1493-11430) ng/mL, 1.30 (0.44-1.86) mg/dL, 117 (40-234) mg/day, and 208 (156-250) mg/day, respectively. Multivariate linear regression analysis revealed that serum FGF23 level was significantly (P<0.05) associated with TmP/GFR negatively and significantly (P<0.05) associated with urinary phosphate excretion positively, even after adjusting for confounders. In contrast, none of the three outcome variates was associated with serum PTH level. Neither serum FGF23 nor PTH level was associated with peritoneal phosphate excretion. The present study indicates that FGF23, but not PTH, is involved in urinary phosphate regulation, even in patients on peritoneal dialysis with residual renal function.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalTherapeutic Apheresis and Dialysis
Volume19
Issue number1
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Peritoneal Dialysis
Parathyroid Hormone
Phosphates
Glomerular Filtration Rate
Serum
Kidney
fibroblast growth factor 23
Moving and Lifting Patients
Chronic Renal Insufficiency
Linear Models
Outpatients
Cross-Sectional Studies
Regression Analysis
Urine

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Fibroblast Growth Factor 23, but not Parathyroid Hormone, Is Associated With Urinary Phosphate Regulation in Patients on Peritoneal Dialysis. / Yamada, Shunsuke; Tsuruya, Kazuhiko; Tokumoto, Masanori; Yoshida, Hisako; Hasegawa, Shoko; Tanaka, Shigeru; Eriguchi, Masahiro; Nakano, Toshiaki; Masutani, Kosuke; Ooboshi, Hiroaki; Kitazono, Takanari.

In: Therapeutic Apheresis and Dialysis, Vol. 19, No. 1, 01.02.2015, p. 73-80.

Research output: Contribution to journalArticle

Yamada, Shunsuke ; Tsuruya, Kazuhiko ; Tokumoto, Masanori ; Yoshida, Hisako ; Hasegawa, Shoko ; Tanaka, Shigeru ; Eriguchi, Masahiro ; Nakano, Toshiaki ; Masutani, Kosuke ; Ooboshi, Hiroaki ; Kitazono, Takanari. / Fibroblast Growth Factor 23, but not Parathyroid Hormone, Is Associated With Urinary Phosphate Regulation in Patients on Peritoneal Dialysis. In: Therapeutic Apheresis and Dialysis. 2015 ; Vol. 19, No. 1. pp. 73-80.
@article{e6ab3d394de046169558b425b1aa1d0e,
title = "Fibroblast Growth Factor 23, but not Parathyroid Hormone, Is Associated With Urinary Phosphate Regulation in Patients on Peritoneal Dialysis",
abstract = "Fibroblast growth factor (FGF) 23 plays an important role in regulation of renal phosphate excretion in patients with chronic kidney disease. However, it remains undetermined whether FGF23 is closely linked to renal phosphate handling in patients with low glomerular filtration rate (GFR). The present cross-sectional study included 52 outpatients undergoing peritoneal dialysis with urine volume≥100mL/day. The primary outcome was level of urinary phosphate excretion, and the secondary outcomes were tubular maximal reabsorption of phosphate normalized to GFR (TmP/GFR), an index of the renal threshold for phosphate excretion, and level of peritoneal phosphate excretion. Variates of interest were serum FGF23 and parathyroid hormone (PTH) levels. The median and interquartile range of serum FGF23 level, TmP/GFR, and total urinary and peritoneal phosphate excretion were 5610 (1493-11430) ng/mL, 1.30 (0.44-1.86) mg/dL, 117 (40-234) mg/day, and 208 (156-250) mg/day, respectively. Multivariate linear regression analysis revealed that serum FGF23 level was significantly (P<0.05) associated with TmP/GFR negatively and significantly (P<0.05) associated with urinary phosphate excretion positively, even after adjusting for confounders. In contrast, none of the three outcome variates was associated with serum PTH level. Neither serum FGF23 nor PTH level was associated with peritoneal phosphate excretion. The present study indicates that FGF23, but not PTH, is involved in urinary phosphate regulation, even in patients on peritoneal dialysis with residual renal function.",
author = "Shunsuke Yamada and Kazuhiko Tsuruya and Masanori Tokumoto and Hisako Yoshida and Shoko Hasegawa and Shigeru Tanaka and Masahiro Eriguchi and Toshiaki Nakano and Kosuke Masutani and Hiroaki Ooboshi and Takanari Kitazono",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/1744-9987.12221",
language = "English",
volume = "19",
pages = "73--80",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Fibroblast Growth Factor 23, but not Parathyroid Hormone, Is Associated With Urinary Phosphate Regulation in Patients on Peritoneal Dialysis

AU - Yamada, Shunsuke

AU - Tsuruya, Kazuhiko

AU - Tokumoto, Masanori

AU - Yoshida, Hisako

AU - Hasegawa, Shoko

AU - Tanaka, Shigeru

AU - Eriguchi, Masahiro

AU - Nakano, Toshiaki

AU - Masutani, Kosuke

AU - Ooboshi, Hiroaki

AU - Kitazono, Takanari

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Fibroblast growth factor (FGF) 23 plays an important role in regulation of renal phosphate excretion in patients with chronic kidney disease. However, it remains undetermined whether FGF23 is closely linked to renal phosphate handling in patients with low glomerular filtration rate (GFR). The present cross-sectional study included 52 outpatients undergoing peritoneal dialysis with urine volume≥100mL/day. The primary outcome was level of urinary phosphate excretion, and the secondary outcomes were tubular maximal reabsorption of phosphate normalized to GFR (TmP/GFR), an index of the renal threshold for phosphate excretion, and level of peritoneal phosphate excretion. Variates of interest were serum FGF23 and parathyroid hormone (PTH) levels. The median and interquartile range of serum FGF23 level, TmP/GFR, and total urinary and peritoneal phosphate excretion were 5610 (1493-11430) ng/mL, 1.30 (0.44-1.86) mg/dL, 117 (40-234) mg/day, and 208 (156-250) mg/day, respectively. Multivariate linear regression analysis revealed that serum FGF23 level was significantly (P<0.05) associated with TmP/GFR negatively and significantly (P<0.05) associated with urinary phosphate excretion positively, even after adjusting for confounders. In contrast, none of the three outcome variates was associated with serum PTH level. Neither serum FGF23 nor PTH level was associated with peritoneal phosphate excretion. The present study indicates that FGF23, but not PTH, is involved in urinary phosphate regulation, even in patients on peritoneal dialysis with residual renal function.

AB - Fibroblast growth factor (FGF) 23 plays an important role in regulation of renal phosphate excretion in patients with chronic kidney disease. However, it remains undetermined whether FGF23 is closely linked to renal phosphate handling in patients with low glomerular filtration rate (GFR). The present cross-sectional study included 52 outpatients undergoing peritoneal dialysis with urine volume≥100mL/day. The primary outcome was level of urinary phosphate excretion, and the secondary outcomes were tubular maximal reabsorption of phosphate normalized to GFR (TmP/GFR), an index of the renal threshold for phosphate excretion, and level of peritoneal phosphate excretion. Variates of interest were serum FGF23 and parathyroid hormone (PTH) levels. The median and interquartile range of serum FGF23 level, TmP/GFR, and total urinary and peritoneal phosphate excretion were 5610 (1493-11430) ng/mL, 1.30 (0.44-1.86) mg/dL, 117 (40-234) mg/day, and 208 (156-250) mg/day, respectively. Multivariate linear regression analysis revealed that serum FGF23 level was significantly (P<0.05) associated with TmP/GFR negatively and significantly (P<0.05) associated with urinary phosphate excretion positively, even after adjusting for confounders. In contrast, none of the three outcome variates was associated with serum PTH level. Neither serum FGF23 nor PTH level was associated with peritoneal phosphate excretion. The present study indicates that FGF23, but not PTH, is involved in urinary phosphate regulation, even in patients on peritoneal dialysis with residual renal function.

UR - http://www.scopus.com/inward/record.url?scp=84922730559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922730559&partnerID=8YFLogxK

U2 - 10.1111/1744-9987.12221

DO - 10.1111/1744-9987.12221

M3 - Article

C2 - 25195562

AN - SCOPUS:84922730559

VL - 19

SP - 73

EP - 80

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 1

ER -